Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations.

Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

Polypharmacy*; Male ; Humans ; Female ; Aged ; Middle Aged ; Pharmaceutical Preparations ; Prevalence ; Drug Interactions ; Comorbidity

Background: The co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug-drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems.
Methods: This study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated.
Results: A large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women - with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis.
Conclusions: DDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records' analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs.
(© 2024. The Author(s).)

Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97. (PMID: 24616171)
JAMIA Open. 2021 Mar 19;4(1):ooab023. (PMID: 33763631)
Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):641-51. (PMID: 17154346)
Arch Gen Psychiatry. 1979 Mar;36(3):327-33. (PMID: 369472)
PLoS One. 2019 Feb 6;14(2):e0210701. (PMID: 30726245)
NPJ Digit Med. 2019 Jul 23;2:74. (PMID: 31341958)
Diabetes. 2006 Jun;55(6):1807-12. (PMID: 16731846)
BMC Geriatr. 2014 Jun 17;14:75. (PMID: 24934411)
Br J Clin Pharmacol. 1998 Mar;45(3):301-8. (PMID: 9517375)
BMC Health Serv Res. 2019 Nov 21;19(1):880. (PMID: 31752835)
N Engl J Med. 1998 Jun 4;338(23):1678-83. (PMID: 9614260)
Pharm World Sci. 2002 Apr;24(2):46-54. (PMID: 12061133)
Lancet. 2012 Jul 7;380(9836):37-43. (PMID: 22579043)
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):82-9. (PMID: 26602064)
Can Fam Physician. 2001 Jun;47:1198-204. (PMID: 11421047)
Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123-1134. (PMID: 30295105)
Sci Rep. 2016 May 27;6:26541. (PMID: 27231197)
J Thromb Haemost. 2007 Jul;5 Suppl 1:255-63. (PMID: 17635734)
Lancet. 2007 Jul 14;370(9582):185-191. (PMID: 17630042)
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. (PMID: 16448873)
BMJ Open. 2019 Aug 30;9(8):e029594. (PMID: 31471439)
PLoS One. 2013 Dec 26;8(12):e85071. (PMID: 24386447)
Int J Clin Pharmacol Ther. 2000 Nov;38(11):504-13. (PMID: 11097142)
Bone. 2013 Dec;57(2):423-8. (PMID: 24063946)
NPJ Digit Med. 2020 Feb 6;3:17. (PMID: 32047862)
BMC Geriatr. 2021 Oct 18;21(1):571. (PMID: 34663238)
CMAJ. 1996 Apr 15;154(8):1177-84. (PMID: 8612253)
PLoS One. 2012;7(3):e33236. (PMID: 22438900)
Expert Rev Clin Pharmacol. 2014 Jul;7(4):533-44. (PMID: 24745854)
Br J Gen Pract. 2012 Dec;62(605):e821-6. (PMID: 23211262)
PLoS One. 2021 Apr 26;16(4):e0250567. (PMID: 33901232)
Med Clin (Barc). 2012 May 19;138(14):617-21. (PMID: 22444996)
J Am Med Inform Assoc. 2017 Mar 1;24(2):331-338. (PMID: 27570216)
JAMA. 1998 Mar 11;279(10):750. (PMID: 9508149)
G Ital Cardiol (Rome). 2018 Jan;19(1):54-61. (PMID: 29451510)
BMC Health Serv Res. 2007 Sep 19;7:147. (PMID: 17880689)
PLoS Comput Biol. 2009 Apr;5(4):e1000353. (PMID: 19360091)
Sci Rep. 2020 Dec 4;10(1):21279. (PMID: 33277524)
Lancet Digit Health. 2023 Jan;5(1):e16-e27. (PMID: 36460578)
Osteoporos Int. 2011 Nov;22(11):2769-88. (PMID: 21360219)
Ann Pharmacother. 2002 Nov;36(11):1675-81. (PMID: 12398558)
J Clin Pharm Ther. 2017 Jun;42(3):276-285. (PMID: 28224645)
Front Pharmacol. 2021 Mar 24;11:624562. (PMID: 33841134)
Eur J Clin Pharmacol. 2014 Mar;70(3):361-7. (PMID: 24362489)
Clinics (Sao Paulo). 2011;66(11):1867-72. (PMID: 22086515)
Nature. 2021 Feb;590(7845):212-215. (PMID: 33568828)
Nat Commun. 2019 Feb 8;10(1):666. (PMID: 30737381)
Sci Rep. 2020 Mar 5;10(1):4101. (PMID: 32139765)
J Am Med Inform Assoc. 2012 Jan-Feb;19(1):79-85. (PMID: 21676938)
JAMA. 2003 Mar 5;289(9):1107-16. (PMID: 12622580)
Nat Commun. 2020 Jun 26;11(1):3223. (PMID: 32591506)
Front Pharmacol. 2020 May 21;11:734. (PMID: 32508654)
J Clin Pharmacol. 2018 Feb;58(2):221-227. (PMID: 28834562)
Pharm Pract (Granada). 2012 Jan;10(1):9-16. (PMID: 24155811)
Nat Commun. 2014 Jun 24;5:4022. (PMID: 24959948)
BMC Med. 2015 Apr 07;13:74. (PMID: 25889849)
Cochrane Database Syst Rev. 2020 May 2;5:CD012852. (PMID: 32358837)
J Clin Pharm Ther. 2017 Apr;42(2):228-233. (PMID: 28111765)
Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1287-94. (PMID: 21702073)
Nat Commun. 2020 Oct 2;11(1):4952. (PMID: 33009368)
Am J Psychiatry. 1998 Jan;155(1):12-21. (PMID: 9433333)
Int J Risk Saf Med. 2013;25(3):185-92. (PMID: 24047689)
Sci Rep. 2020 Oct 9;10(1):16879. (PMID: 33037233)
Stud Health Technol Inform. 2022 Jun 6;290:380-384. (PMID: 35673040)
Am J Manag Care. 2010 Sep;16(9):e228-34. (PMID: 21250399)
Circ Heart Fail. 2018 Dec;11(12):e005266. (PMID: 30562095)
BMJ. 2008 Jan 5;336(7634):2-3. (PMID: 18174564)
Drugs Aging. 2009;26(6):475-82. (PMID: 19591522)
Br J Clin Pharmacol. 2010 Aug;70(2):258-67. (PMID: 20653679)
Eur J Clin Pharmacol. 2008 Oct;64(10):999-1004. (PMID: 18604529)

R01 LM012832 United States LM NLM NIH HHS

Keywords: Drug–drug interactions; Electronic health records; Multimorbidity; Polypharmacy

0 (Pharmaceutical Preparations)

Date Created: 20240418 Date Completed: 20240422 Latest Revision: 20240426

20240426

PMC11027217

10.1186/s12916-024-03384-1

38637816